Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  arsenic trioxide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 61 for your search:
Start Over
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LAP-R2007, NCT00504764
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Enrolling by invitation
Age: 18 to 75
Sponsor: Other
Protocol IDs: GDREC2013109H(R1), NCT01861912
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI
Protocol IDs: NCI-2012-02811, C9710, CDR0000067126, CALGB-C9710, U10CA031946, CAN-NCIC-AL3, COG-C9710, ECOG-C9710, SWOG-C9710, CAN-NCIC-C9710, AL3, NCT00003934
Phase III Trial in Acute Promyelocytic Leukemia Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: APL0406, GIMEMA-SAL-APL0406, EUDRACT-2006-006188-22, GIMEMA-DSL-APL0406, EU-20725, NCT00482833
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S0521, U10CA032102, SWOG-S0521, NCT00492856
Phase III Study of Risk-Adapted Induction Chemotherapy, Risk-Adapted Consolidation Combination Chemotherapy Including Arsenic Trioxide, and Maintenance Combination Chemotherapy in Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 2 to 21
Sponsor: NCI
Protocol IDs: COG-AAML0631, COG-AAML0631, AAML0631, NCT00866918
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: CDR0000066617, WU-98-0185, NCI-V98-1466, NCT00008697
Arsenic Trioxide in Combination With Cytarabine in Patients With High-Risk MDS and Poor-Prognosis AML
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 0603-887, NCT00195104
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 75 and under
Sponsor: Other
Protocol IDs: 2005-0893, NCT00469209
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 1888.00, FHCRC-1888.00, CDR0000380742, NCT00093366
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 04C1, CDR0000456504, STU00007792, NCT00275067
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000269319, OHSU-UCLA-0206062, OHSU-HEM-02001-L, OHSU-1096, NCT00053248
Phase II Study of Arsenic Trioxide in Patients with Relapsed or Refractory Acute Promyelocytic Leukemia (Summary Last Modified 07/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: No age specified
Sponsor: NCI
Protocol IDs: PLRX-AS01, MSKCC-98025, NCI-H98-0012
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: CDR0000067382, AECM-1199908270, NCI-T99-0077, AECM-CCRC-9929, T99-0077, NCT00004149
Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Chronic Myelogenous Leukemia (Summary Last Modified 10/2001)
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: MSKCC-99076A, NCI-190, NCT00005618, 190
Phase II Study of Arsenic Trioxide in Patients With Stage IVB or Recurrent Cervical Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 17 and over
Sponsor: NCI
Protocol IDs: MSKCC-00018, NCI-30, NCT00005999, 30
Phase II Study of Arsenic Trioxide in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-9998, NCT00006008, E9998
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02789, CALGB-99903, U10CA031946, CLB-99903, NCT00009867
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 00-072, MSKCC-00072, NCI-H01-0073, NCT00016159
Start Over